Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124130702 | 12413070 | 2 | F | 201605 | 20160623 | 20160527 | 20160713 | PER | US-SHIRE-US201605989 | SHIRE | 42.48 | YR | F | Y | 0.00000 | 20160709 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124130702 | 12413070 | 1 | PS | VYVANSE | LISDEXAMFETAMINE DIMESYLATE | 1 | Oral | 20 MG, 1X/DAY:QD | U | U | 3139715 | 21977 | 20 | MG | CAPSULE | QD | |||
124130702 | 12413070 | 2 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Unknown | UNK, UNKNOWN | 0 | ||||||||||
124130702 | 12413070 | 3 | C | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Unknown | UNK, UNKNOWN | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124130702 | 12413070 | 1 | Attention deficit/hyperactivity disorder |
124130702 | 12413070 | 2 | Product used for unknown indication |
124130702 | 12413070 | 3 | Product used for unknown indication |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124130702 | 12413070 | Drug ineffective | |
124130702 | 12413070 | Product quality issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |